A Phase II Trial Evaluating the Safety of Rapid Infusion of Ofatumumab in Patients with Previously Treated Chronic Lymphocytic Leukemia

LESSONS LEARNED. Ofatumumab infusion reactions can be diminished by escalating the dose rate in individual patients in sequential infusions. BACKGROUND. Ofatumumab (OFA) is a fully humanized, anti‐CD20 antibody approved for use in chronic lymphocytic leukemia (CLL). The recommended administration re...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncologist
Autori principali: Donnellan, William, Berdeja, Jesus G., Shipley, Diana, Arrowsmith, Edward R., Wright, David, Lunin, Scott, Brown, Richard, Essell, James H., Flinn, Ian W.
Natura: Artigo
Lingua:Inglês
Pubblicazione: AlphaMed Press 2017
Soggetti:
Clinical Trial Results
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5634770/
https://ncbi.nlm.nih.gov/pubmed/28687625
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0236
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi